FOR IMMEDIATE RELEASE
Contact: Kimberly N. Alleyne
Made to Save executive director, Chris Wyant, released the following statement regarding the CDC and FDA’s recommendation to resume administration of the Johnson & Johnson COVID-19 vaccine.
Washington, D.C. — Today, the Advisory Committee on Immunization Practices (ACIP), which includes doctors and public-health officials, advised the FDA and CDC to resume administration of Johnson & Johnson COVID-19 vaccine, and the FDA and CDC moved forward with their recommendation.
While we know concerns may linger, we are determined to increase vaccine confidence and access — especially among the populations that have been hardest hit by the pandemic. We are standing strong in our roles as an advocate for those communities to ensure they have access to the vaccines, and as an information hub that quickly shares concerns, ideas and promising practices, and guidance we hear from our trusted community partners.
The pause helped inform clinicians how to identify and appropriately treat these uncommon clots, which can be appropriately treated if identified. Restarting administration of the Johnson & Johnson vaccine means tremendous, potential benefits for individuals and the population, as more people will have access to vaccines.
As part of COVID-19 vaccine research and development, federal agencies have been steadfast in ensuring vaccine safety and efficacy. The previous pause in the vaccine signaled that the system worked as it should, as does the recommendation to end the pause.
We encourage individuals to maintain their vaccination plan or make an appointment if they haven’t yet, or to talk to their family and friends about getting vaccinated. Individual vaccinations are our only path to getting back to the experiences, occasions, and people we cherish most.